Physician profile

Jared S Weiner

Oral & Maxillofacial Surgery · Feasterville, PA

NPI 1598003121

$900.19

in general payments reported to CMS, 2019-2025

4 companies · none reported in 2025

See the full distribution for Oral & Maxillofacial Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$375.00
Food and Beverage$87.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Straumann USA LLC $494.60 2020-2024
Nobel Biocare USA $193.32 2021-2023 Nobelactive
Geistlich Pharma, North America, INC. $148.45 2022-2023 Bio-Gide
Salvin Dental Specialties, INC. $63.82 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jared S Weiner

$900.19

in general payments reported 2019-2025

Years
2020-2024
Top company
Straumann USA LLC

https://glasscript.com/doctor/1344025/jared-s-weiner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.